Evidence map›Paper›PMID 29618330›Full record

ArticleBMC infectious diseases2018

Filaria specific antibody response profiling in plasma from anti-retroviral naïve Loa loa microfilaraemic HIV-1 infected people.

Ghislain Donald Njambe Priso, Abel Lissom, Loveline N Ngu, Nadesh N Nji, Jules Colince Tchadji, Thibau Flaurant Tchouangueu, Georgia E Ambada, Carole Stéphanie Sake Ngane, Brigitte Laure Dafeu, Larissa Djukouo and 12 more

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Tissue Parasites in HIV Infection.Current infectious disease reports · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 7 institutions in 5 countries.

Ghislain Donald Njambe PrisoLaboratory of vaccinology/biobanking, CIRCB, Messa, Yaounde, Cameroon.
Abel LissomLaboratory of vaccinology/biobanking, CIRCB, Messa, Yaounde, Cameroon.
Loveline N NguLaboratory of vaccinology/biobanking, CIRCB, Messa, Yaounde, Cameroon.
Nadesh N NjiLaboratory of vaccinology/biobanking, CIRCB, Messa, Yaounde, Cameroon.
Jules Colince TchadjiLaboratory of vaccinology/biobanking, CIRCB, Messa, Yaounde, Cameroon.
Thibau Flaurant TchouangueuLaboratory of vaccinology/biobanking, CIRCB, Messa, Yaounde, Cameroon.
Georgia E AmbadaLaboratory of vaccinology/biobanking, CIRCB, Messa, Yaounde, Cameroon.
Carole Stéphanie Sake NganeLaboratory of vaccinology/biobanking, CIRCB, Messa, Yaounde, Cameroon.
Brigitte Laure DafeuLaboratory of vaccinology/biobanking, CIRCB, Messa, Yaounde, Cameroon.
Larissa DjukouoLaboratory of vaccinology/biobanking, CIRCB, Messa, Yaounde, Cameroon.
Inès NyebeLaboratory of vaccinology/biobanking, CIRCB, Messa, Yaounde, Cameroon.
Suzanne MagagoumLaboratory of vaccinology/biobanking, CIRCB, Messa, Yaounde, Cameroon.
Apeh Alfred NgohLaboratory of vaccinology/biobanking, CIRCB, Messa, Yaounde, Cameroon.
Ouambo Fotso HerveLaboratory of vaccinology/biobanking, CIRCB, Messa, Yaounde, Cameroon.
Rosario GarciaCSCB (Centre de santé catholique de Bikop), Bikop, Cameroon.
Anna GutiérrezCSCB (Centre de santé catholique de Bikop), Bikop, Cameroon.
Arinze S OkoliGenØk - Centre for Biosafety, Tromsø, Norway.
Charles O EsimoneDepartment of Pharmaceutical Microbiology & Biotechnology, Nnamdi Azikiwe University, Awka, Nigeria.
Flobert NjiokouDepartment of animal biology and Phisiology, University of Yaounde I, Yaounde, Cameroon.
Chae Gyu ParkLaboratory of Immunology, Brain Korea 21 PLUS Project for Medical Science, Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
Alain Bopda WaffoDepartment of Biological Sciences, College STEM, 1627 Hall Street, Montgomery, AL, 36101, USA.
Godwin W NchindaLaboratory of vaccinology/biobanking, CIRCB, Messa, Yaounde, Cameroon. nsehleseh@gmail.com.
Centre International De Reference Chantal Biya · CMUniversité de Yaoundé I · CMGenØk · NOMontgomery College · USNnamdi Azikiwe University · NGUniversity of Buea · CMYonsei University · KR

Funding

African Korean collaborative grand NRF-2013KIA3A1A09076155CIRCB PTA-2012-2017EDCTP TA.2010.40200.016Grand Challenges Canada 0121-01TWAS 12059RG/bio/af/ac_G
6 · The paper itself

Abstract

backgroundIn West and Central Africa areas of endemic Loa loa infections overlap with regions of high prevalence of human immunodeficiency virus type 1 (HIV-1) infections. Because individuals in this region are exposed to filarial parasites from birth, most HIV-1 infected individuals invariably also have a history of filarial parasite infection. Since HIV-1 infection both depletes immune system and maintains it in perpetual inflammation, this can hamper Loa loa filarial parasite mediated immune modulation, leading to enhanced loaisis.

methodsIn this study we have assessed in plasma from asymptomatic anti-retroviral (ARV) naïve Loa loa microfilaraemic HIV-1 infected people the filarial antibody responses specific to a filariasis composite antigen consisting of Wbgp29-BmR1-BmM14-WbSXP. The antibody responses specific to the filariasis composite antigen was determined by enzyme linked immunosorbent assay (ELISA) in plasma from ARV naïve Loa loa microfilaraemic HIV-1 infected participants. In addition the filarial antigen specific IgG antibody subclass profiles were also determined for both HIV-1 positive and negative people.

resultsBoth Loa loa microfilaraemic HIV-1 positive and negative individuals showed significantly higher plasma levels of IgG1 (P < 0.0001), IgG2 (P < 0.0001) and IgM (P < 0.0001) relative to amicrofilaraemic participants. A significant increase in IgE (P < 0.0001) was observed exclusively in Loa loa microfilaraemic HIV-1 infected people. In contrast there was a significant reduction in the level of IgG4 (p < 0.0001) and IgG3 (P < 0.0001) in Loa loa microfilaraemic HIV-1 infected individuals.

conclusionsLoa loa microfilaraemia in ARV naïve HIV-1 infected people through differential reduction of plasma levels of filarial antigen specific IgG3, IgG4 and a significant increase in plasma levels of filarial antigen specific IgE could diminish Loa loa mediated immune-regulation. This in effect can result to increase loaisis mediated immunopathology in antiretroviral naive HIV-1 infected people.

Indexed as

AdultAgedAnimalsAntibodies, HelminthAntibody FormationAntigens, HelminthAnti-Retroviral AgentsEnzyme-Linked Immunosorbent AssayFemaleHIV InfectionsHumansImmunoglobulin EImmunoglobulin GLoaLoiasisMaleAntibodies, HelminthAntigens, HelminthAnti-Retroviral AgentsImmunoglobulin EImmunoglobulin GAfrican eye wormHIV-1LoaisisLoa loaMicrofilaraemia

Identifiers

PMID29618330
PMCPMC5885382
OpenAlexW2795603447

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.